Clinical Edge Journal Scan

Gastric transcatheter chemoembolization shows promise against advanced gastric cancer with obstruction


 

Key clinical point: Gastric transcatheter chemoembolization (GTC) is a safe and effective alternative treatment method for advanced gastric cancer with obstruction.

Major finding: All patients achieved successful selection of tumor-feeding blood vessels and injection of chemotherapeutics and embolic agents, while 22 achieved a gastric outlet obstruction scoring system (GOOSS) score of ≥2. The median time of GTC was 83 minutes, and the median time of hospitalization after GTC was 3 days. One patient experienced abdominal pain during and after GTC. The pre- and post-intervention GOOSS scores were 1 and 2, respectively (P = .000).

Study details: This retrospective study included 42 patients with advanced gastric cancer complicated with obstruction who underwent GTC.

Disclosures: This study was supported by the Chongqing Science and Health Joint Project, China. The authors declared no conflicts of interest.

Source: Peng D et al. Gastric transcatheter chemoembolization can resolve advanced gastric cancer presenting with obstruction. Front Surg. 2022;9:1004064 (Oct 20). Doi: 10.3389/fsurg.2022.1004064

Recommended Reading

Excellent prognostic ability of neutrophil-to-lymphocyte ratio in CRC liver metastasis
MDedge Hematology and Oncology
mCRC: Triplet+bevacizumab offers survival advantage even in patients with bone metastasis
MDedge Hematology and Oncology
Comparative analysis of total neoadjuvant therapy vs standard therapy in LARC
MDedge Hematology and Oncology
ctDNA detection following curative surgery for colorectal cancer predicts poor prognosis
MDedge Hematology and Oncology
Bemarituzumab shows promising efficacy in patients with FGFR2b-selected gastric cancer
MDedge Hematology and Oncology
Gastric ulcer increases the risk for gastric cancer
MDedge Hematology and Oncology
Preoperative D-dimer-to-albumin ratio: A biomarker for long-term prognosis in gastric cancer
MDedge Hematology and Oncology
Disease progression pattern linked with poor prognosis in advanced gastric cancer patients on nivolumab
MDedge Hematology and Oncology
Intestinal metaplasia before H. pylori eradication hints at post-eradication gastric cancer surveillance
MDedge Hematology and Oncology
Gastric cancer: Sarcopenic obesity is a risk factor for poorer outcomes after gastrectomy
MDedge Hematology and Oncology